UPDATE 1-Cortex to resume Ampakine trial at all dosage levels

(Reuters) - The company now has permission from the Food and Drug
Administration to resume trial with 600mg and 1200mg doses of
the drug in mild-to-moderate Alzheimer's patients.




FDA had previously limited the dosage to lower levels. The
study was originally designed with doses of 200mg, 600mg and
1200mg.
The company's shares rose more than 25 percent in midday
trade, making them the highest percentage gainer on the
American Stock Exchange.


Read more at Reuters.com Government Filings News